Literature DB >> 19046942

Aberrant silencing of the endocrine peptide gene tachykinin-1 in gastric cancer.

Stefan David1, Takatsugu Kan, Yulan Cheng, Rachana Agarwal, Zhe Jin, Yuriko Mori.   

Abstract

Tachykinin-1 (TAC1) is the precursor protein for neuroendocrine peptides, including substance P, and is centrally involved in gastric secretion, motility, mucosal immunity, and cell proliferation. Here we report aberrant silencing of TAC1 in gastric cancer (GC) by promoter hypermethylation. TAC1 methylation and mRNA expression in 47 primary GCs and 41 noncancerous gastric mucosae (NLs) were analyzed by utilizing real-time quantitative PCR-based assays. TAC1 methylation was more prevalent in GCs than in NLs: 21 (45%) of 47 GCs versus 6 (15%) of 41 NLs (p<0.01). Microsatellite instability was also associated with TAC1 methylation in GCs. There was no significant association between TAC1 methylation and age, gender, stage, histological differentiation, or the presence of Helicobacter pylori. TAC1 mRNA was markedly downregulated in GCs relative to NLs. 5-Aza-2'-deoxycytidine-induced demethylation of the TAC1 promoter resulted in TAC1 mRNA upregulation. Further studies are indicated to elucidate the functional involvement of TAC1 in gastric carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19046942     DOI: 10.1016/j.bbrc.2008.11.078

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Association of genetic variants in tachykinins pathway genes with colorectal cancer risk.

Authors:  Yunxian Yu; Yifeng Pan; Mingjuan Jin; Mingwu Zhang; Shanchun Zhang; Qilong Li; Xia Jiang; Hui Liu; Jing Guo; He Liu; Kun Chen
Journal:  Int J Colorectal Dis       Date:  2012-06-26       Impact factor: 2.571

2.  Epigenetic control of cancer by neuropeptides.

Authors:  Karina Galoian; Parthik Patel
Journal:  Biomed Rep       Date:  2016-11-08

3.  Frequent promoter hypermethylation of tachykinin-1 and tachykinin receptor type 1 is a potential biomarker for head and neck cancer.

Authors:  Kiyoshi Misawa; Takeharu Kanazawa; Yuki Misawa; Atsushi Imai; Takayuki Uehara; Daiki Mochizuki; Shiori Endo; Goro Takahashi; Hiroyuki Mineta
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-19       Impact factor: 4.553

4.  Aberrant methylation inactivates somatostatin and somatostatin receptor type 1 in head and neck squamous cell carcinoma.

Authors:  Kiyoshi Misawa; Yuki Misawa; Haruki Kondo; Daiki Mochizuki; Atsushi Imai; Hirofumi Fukushima; Takayuki Uehara; Takeharu Kanazawa; Hiroyuki Mineta
Journal:  PLoS One       Date:  2015-03-03       Impact factor: 3.240

5.  A Novel Purine and Uric Metabolism Signature Predicting the Prognosis of Hepatocellular Carcinoma.

Authors:  Shengjie Yang; Baoying Zhang; Weijuan Tan; Lu Qi; Xiao Ma; Xinghe Wang
Journal:  Front Genet       Date:  2022-07-12       Impact factor: 4.772

6.  Silencing of claudin-11 is associated with increased invasiveness of gastric cancer cells.

Authors:  Rachana Agarwal; Yuriko Mori; Yulan Cheng; Zhe Jin; Alexandru V Olaru; James P Hamilton; Stefan David; Florin M Selaru; Jian Yang; John M Abraham; Elizabeth Montgomery; Patrice J Morin; Stephen J Meltzer
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

7.  A contrasting function for miR-137 in embryonic mammogenesis and adult breast carcinogenesis.

Authors:  Jong-Min Lee; Kyoung-Won Cho; Eun-Jung Kim; Qinghuang Tang; Kye-Seong Kim; Cheryll Tickle; Han-Sung Jung
Journal:  Oncotarget       Date:  2015-09-08

8.  Prognostic value of aberrant promoter hypermethylation of tumor-related genes in early-stage head and neck cancer.

Authors:  Kiyoshi Misawa; Daiki Mochizuki; Atsushi Imai; Shiori Endo; Masato Mima; Yuki Misawa; Takeharu Kanazawa; Thomas E Carey; Hiroyuki Mineta
Journal:  Oncotarget       Date:  2016-05-03

9.  Identification of a novel 10 immune-related genes signature as a prognostic biomarker panel for gastric cancer.

Authors:  Tingna Chen; Chaogang Yang; Rongzhang Dou; Bin Xiong
Journal:  Cancer Med       Date:  2021-08-12       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.